FDA Summary Basis of Approval – Naltrexone Hydrochloride (Revia) Tablet 50 mg for TEVA WOMENS HEALTH INC, NDA N018932

FDA Summary Basis of Approval – Naltrexone Hydrochloride (Revia) Tablet 50 mg for TEVA WOMENS HEALTH INC, NDA N018932

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request Contents: Summary Basis of Approval for Naltrexone Hydrochloride (Revia) Tablet Oral 50 mg for TEVA WOMENS HEALTH INC, NDA N018932
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details